drugset / Trial / NCT00281866
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
Phase 2
Completed
37 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedTreatment
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent and/or metastatic head and neck cancer.
Timeline
- Start
- 2005-07
- Primary completion
- 2006-10
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |